TrialInternational journal of cancer2025

Hematologic and molecular responses to ropeginterferon alfa-2b therapy of polycythemia vera: 48-week results from a prospective study.

Seug Yun Yoon et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.